References
- Lim P., Dow E., Brennan G., Jung R., MacDonald T. High prevalence of primary aldosteronism in the Tayside hypertension clinic population. J Human Hypertens 2000; 14: 311–315
- Kaplan N. Cautions over the current epidemic of primary aldosteronism. Lancet 2001; 357: 953–954
- Rayner B., Opie L., Davidson J. The aldosterone/renin ratio as a screening test for primary aldosteronism. South African Med J 2000; 90: 394–400
- Lim P., Rodgers P., Cardale K., Watson A., MacDonald T. Potentially high prevalence of primary adosteronism in a primary‐care population. Lancet 1999; 353: 40
- Ohkubo T., Hozawa A., Yamaguchi J., Kikuyi M., Ohmori K., Michimata M., et al. Prognostic significance of the nocturnal decline in blood pressure in individuals with and without high 24‐h blood pressure: The Ohasama study. J Hypertens 2002; 20: 2183–2189
- Gordon R., Ziesk M., Tunny T., Stowasser M., Klemm S. Evidence that primary aldosteronism may not be uncommon: 12% incidence among antihypertensive drug trial volunteers. Clin Exp Pharmacol Physiol 1993; 20: 296–298
- Ganguly A. Primary aldosteronism. N Engl J Med 1998; 339: 1828–1834
- Kaplan N. Clinical hypertension. Williams and Wilkins, Baltimore 1994
- Conn J. Plasma renin activity in primary aldosteronism. Importance in differential diagnosis and in research of essential hypertension. JAMA 1964; 190: 222–225
- Vasan R. S., Evans J. C., Larson M. G., Wilson P. W. F., Meigs J. B., Rifai N., et al. Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med 2004; 351: 33–41
- Lim P., Young W., MacDonald T. A review of the medical treatment of primary aldosteronism. J Hypertens 2000; 19: 353–361
- Weber K., Sun Y., Campbell S., Slight S., Ganham V., Griffing G., et al. Chronic mineralocorticoid excess and cardiovascular remodelling. Steroids 1995; 60: 125–132
- Lim P., Jung R., MacDonald T. Raised aldosterone to renin ratio predicts ant‐hypertensive efficacy of spironolactone. A prospective cohort follow‐up study. Br J Clin Pharmacol 1999; 48: 756–760
- Prasad N., Isles C. Fortnightly review: Ambulatory blood pressure monitoring: A guide for general practitioners. BMJ 1996; 313: 1535–1541
- Gibbs C., Murray S., Beevers D. The clinical value of ambulatory blood pressure monitoring. Heart 1998; 1998: 225–228
- Pickering T. Ambulatory blood pressure monitoring. Curr Hypertens Rep 2000; 2: 558–564
- Middeke M., Schrader J. Nocturnal blood pressure in normotensive subjects and those with white coat, primary, and secondary hypertension. BMJ 1994; 308: 630–632
- Buhler F., Laragh J., Baer L., Vaughan E., Brunner H. Propranolol inhibition of renin secretion: A specific approach to diagnosis and treatment of renin‐dependent hypertensive diseases. N Engl J Med 1972; 287: 1209–1214
- Gordon M., Williams G., Hollenberg N. Renal and adrenal responsiveness to angiotensin II: Influence of beta‐blockage. Endocr Res 1992; 18: 115–131
- Stowasser M., Gordon R., Rutherford J., Nikwan N., Daunt N., Slater G. Diagnosis and management of primary aldosteronism. J renin angiotensin aldosterone Syst 2001; 2: 156–169
- Young W. Primary aldosteronism: Update in diagnosis and treatment. The Endocrinologist 1997; 7: 213–221
- Gordon R. Primary aldosteronism. J Endocrinol Invest 1995; 18: 495–511
- Fiad T., Cunningham S., Hayes F., McKenna T. Effects of nifedipine treatment on the renin–angiotensin–aldosterone axis. J Clin Endocrinol Metab 1997; 82: 457–460
- Brown M., Hopper R. Calcium‐channel blockade can mask the diagnosis of Conn's syndrome. Postgrad Med J 1999; 82: 457–460
- Foo R., O'Shaughnessy K. M., Brown M. J. Hyperaldosteronism: Recent concepts, diagnosis, and management. Postgrad Med J 2001; 77: 639–644